Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "cancer treatment" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 99
Tytuł:
Nanotechnology in oncology - current state of knowledge
Autorzy:
Laskowska, Dorota
Ziółkowska, Ewa
Mitura, Katarzyna
Powiązania:
https://bibliotekanauki.pl/articles/286080.pdf
Data publikacji:
2019
Wydawca:
Akademia Górniczo-Hutnicza im. Stanisława Staszica w Krakowie. Polskie Towarzystwo Biominerałów
Tematy:
nanotechnology
oncology
nanostructures
cancer treatment
Opis:
Nanotechnology is an interdisciplinary area of science devoted to the production and testing of nanostructures - defined as forms of the matter organizations the size of which does not exceed 100 nm. It is a quickly developing area of science with many applications in different areas of life, for example in engineering, computing, medicine, pharmacy, andagriculture. One of the problems of contemporary oncology is the low specificity of applied therapies. Most currently used chemiopharmaceuticals have systemic effects which not only affect cancer cells but alsohealthy tissues. Complications after chemotherapy observed in many patients are bone marrow deficiency(neutropenin, thrombocytopenia, anemia), damageto the nervous system (neurotoxicity), myocardium(cardiotoxicity) and pulmonary parenchyma. Similarly, in radiotherapy, ionizing radiation destroys the healthy tissues in the irradiation field. The side effects of radiation therapy may include fatigue, skin reactions, and impairment of tissue and organ functions. According to studies, nanostructures are an opportunity to overcome these limitations. The most popular nanostructures used in medicine are liposomes, silver and gold nanoparticles, magnetic nanoparticles, carbonnanotubes, and dendrimers. The purpose of this article is to present the current state of knowledge on the use of available nanotechnology solutions in pharmacology and cancer treatment.
Źródło:
Engineering of Biomaterials; 2019, 22, 152; 2-9
1429-7248
Pojawia się w:
Engineering of Biomaterials
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Investigating the anti-cancer properties of Trametes gibbosa extract on human colon cancer cells
Badanie antykancerogennych właściwości ekstraktu z wrośniaka garbatego (Trametes gibbosa)
Autorzy:
Siewert, Barbara
Powiązania:
https://bibliotekanauki.pl/articles/32388082.pdf
Data publikacji:
2023
Wydawca:
Fundacja PSC
Tematy:
Trametes gibbosa
colon cancer
cancer treatment
fungi
Opis:
Trametes gibbosa, also referred to as lumpy bracket, is a fungus belonging to the Polyporaceae with natural bioactive compounds that have aroused great interest for their potential benefits in human health. This pilot study aimed to investigate the anti-cancer effect of Trametes gibbosa extract against the HCT-116 cell line (human colorectal cancer cells). The extract was obtained by macerating dry biomass with 3 solvents: acetone, isopropyl alcohol and DCM, isolating established anticancer agents –polysaccharide complexes (PSK and PSP) from the extract, and then being dissolved. Cellular toxicity was assessed by trypan blue staining, determining the effect of 1- and 24-hour continuous exposure to the extract of varying concentrations: 100 µl/mL, 200 µl/mL, 500 µl/mL, 1000 µl/ mL. Results have demonstrated a cytotoxic effect in time- and dose-dependent manners. The proposed cellular mechanisms behind the results are most likely apoptosis followed by secondary necrotic cell death, as the literature suggests, although that remains unclear and requires further experiments. Within the course of consecutive studies, it can be established whether the extract or the compounds contained may hold promise for clinical use, e.g., for adjuvant therapy.
Źródło:
Alcumena. Pismo Interdyscyplinarne; 2023, 2(14); 101-112
2719-9851
Pojawia się w:
Alcumena. Pismo Interdyscyplinarne
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Innovations in lung cancer treatment
Autorzy:
Sieńko, Anna
Rożenek, Karolina
Nalewaj, Piotr
Bożyk, Aleksandra
Krawczyk, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/1178237.pdf
Data publikacji:
2018
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
Immunotherapy
Lung cancer
Lung cancer treatment
targeted therapy
Opis:
Lung cancer is associated with one of the highest mortality rates among malignant tumors. It is the main death cause of men and women in Poland where over 15 000 men and 7 000 women die with this diagnosis annually. 1.7 million people die every year due to lung cancer in the world. Two main types of lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The history of lung cancer treatment begins with surgical approach followed by addition of chemotherapy and radiotherapy, which were used either separately or in combination depending on the stage of the lung cancer. Many somatic mutations were identified and molecularly targeted therapies could have been established. One of the oldest and the best known group of molecularly targeted drugs used in lung cancer treatment are tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR). First EGFR-TKI was gefitinib, which has been examined in clinical trials before erlotinib, afatinib, dacomitinib and osimertinib. EGFR-TKIs increased overall survival (OS) with significantly less side effects when compared to standard chemotherapy. Another group of molecularly targeted drugs are anaplastic lymphoma (ALK) kinase inhibitors such as crizotinib, alectinib and ceritinib. Another innovation which was introduced in NSCLC treatment was immunotherapy. Its effect is based on modification of immune system leading to activation of cytotoxic T lymphocytes (CTL). Currently nivolumab and pembrolizumab (anti-PD1 antibodies) as well as atezoliumab (anti-PD-L1 antibody) are being used in NSCLC patients. The discovery of innovative therapies for NSCLC patients resulted in significant extension of patients' life expectancy while minimizing the side effects of such therapy. Moreover, the quality of patients’ life was significantly improved. However, important problems still remain to be solved: overcoming the resistance in the course of molecularly targeted therapies and the lack of predictive factors that determine the effectiveness of immunotherapy.
Źródło:
World Scientific News; 2018, 93; 115-124
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Zespół przewlekłego zmęczenia u chorych z rozpoznaniem nowotworu złośliwego
Chronic fatigue syndrome in patients diagnosed with malignant neoplasm
Autorzy:
Golon, K.
Karczmarek-Borowska, B.
Powiązania:
https://bibliotekanauki.pl/articles/136116.pdf
Data publikacji:
2017
Wydawca:
Wyższa Szkoła Techniczno-Ekonomiczna w Szczecinie
Tematy:
zespół przewlekłego zmęczenia
nowotwór złośliwy
leczenie przeciwnowotworowe
chronic fatigue syndrome
cancer
cancer treatment
Opis:
Wstęp i cele: Zespołem przewlekłego zmęczenia określa się długotrwałe odczuwanie osłabienia przez chorych, związane z obecnością nowotworu lub leczeniem przeciwnowotworowym. Występuje u 70-100% pacjentów poddanych chemioterapii, immunoterapii, radioterapii, a także leczeniu chirurgicznemu. Wystąpienie ZPZ może być związane z obecnością zaawansowanej choroby nowotworowej, jej leczeniem, brakiem aktywności fizycznej, ale także współistnieć z chorobami układu krążenia, oddechowego, niewydolności narządów, wyniszczeniem nowotworowym, depresją. Najprostszą formą oceny zmęczenia jest badanie jego natężenia. Do oceny najlepiej posłużyć się linearną skalą numeryczną (NRS). Przy rozpoznaniu łagodnego stopnia postępowanie opiera się na edukacji chorych celem zmiany trybu życia, żywienia. Przy nasilonym stopniu podejmuje się leczenie odwracalnych przyczyn ZPZ, ewentualnie należy rozważyć postępowanie farmakologiczne. Materiał i metody: Zastosowano metodę przeglądową literatury. Wnioski: Objawy ZPZ mogą się różnić u poszczególnych osób, mogą mieć różną postać.
Introduction and aim: Chronic fatigue syndrome (CFS) is determined as prolonged fatigue sensation in patients which is evoked by cancer or cancer treatment. It occurs in 70-100% of patients undergoing chemotherapy, immunotherapy, radiotherapy and surgical treatment. CFS occurrence may be associated with the presence of advanced cancer, its treatment, lack of physical activity, but also coexisting cardiovascular or respiratory diseases, organ failure, cancer cachexia, depression. The simplest form of fatigue evaluation is to measure its intensity with a linear numerical scale. When a mild CFS is detected, the conduct is based on patient education on lifestyle and nutrition. Severe CFS requires treatment of reversible causes of CFS or pharmacotherapy may be considered. Material and methods: The literature review method was used. Conclusion: Symptoms of CFS may vary from person to person, and may vary in appearance.
Źródło:
Problemy Nauk Stosowanych; 2017, 6; 127-134
2300-6110
Pojawia się w:
Problemy Nauk Stosowanych
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Development and production of radioactive sources used for cancer treatment in Brazil
Autorzy:
Rostelato, M. E. C. M.
Rela, P. R.
Zeituni, C. A.
Feher, A.
Manzoli, J. E.
Moura, J. A.
Moura, E. S.
Silva, C. P. G.
Powiązania:
https://bibliotekanauki.pl/articles/148305.pdf
Data publikacji:
2008
Wydawca:
Instytut Chemii i Techniki Jądrowej
Tematy:
radioactive sources production
iodine-125 seeds
iridium-192 wires
brachytherapy
cancer treatment
Opis:
The number of cancer patients in Brazil is increasing and part of the patients are submitted to brachytherapy treatment using iridium-192 wire and iodine-125 radioactive seeds. The Nuclear Energy Research Institute established a programme to produce iridium-192 wire and iodine-125 radioactive seeds. With the purpose of settling a laboratory for iridium-192 sources production, a wire activation method was developed and a hot cell for the wire manipulation, quality assurance and packaging was built. The iodine-125 seeds consist of a welded titanium capsule containing iodine-125 adsorbed onto a silver rod. Concerning the setup of the local production, the following activities were carried out: superficial treatment of the silver rod, development of a process to absorb the iodine in the silver rod, welding methodology to seal the seeds, leakage and contamination test and source activity measurement.
Źródło:
Nukleonika; 2008, 53, suppl. 2; 99-103
0029-5922
1508-5791
Pojawia się w:
Nukleonika
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Badania nad terapią BNCT w Polsce i na świecie
Research on BNCT in Poland and in the world
Autorzy:
Knake, Natalia
Maciak, Maciej
Maliszewska-Olejniczak, Kamila
Tymińska, Katarzyna
Murawski, Łukasz
Madejowski, Gaweł
Wójciuk, Karolina
Michaś, Edyta
Wojtania, Grzegorz
Kuć, Michał
Dróżdż, Agnieszka
Gryziński, Michał A.
Powiązania:
https://bibliotekanauki.pl/articles/986658.pdf
Data publikacji:
2019
Wydawca:
Indygo Zahir Media
Tematy:
BNCT
hadronoterapia
leczenie nowotworów
związki boru
neutrony
hadron therapy
cancer treatment
boron compounds
neutrons
Opis:
Przy Reaktorze MARIA w Narodowym Centrum Badań Jądrowych (NCBJ) powstaje stanowisko do badań nad terapią borowo-neutronową (BNCT). Terapia polega na napromienianiu nowotworu wiązką neutronów o odpowiednich parametrach po uprzednim podaniu pacjentowi związku boru, który w wyniku określonych mechanizmów gromadzi się głównie w komórkach rakowych. W wyniku reakcji 10B(n,α)7Li emitowane są cząstki jonizujące powodujące zniszczenie tylko tych komórek, w których zgromadzony jest bor [1]. Badania kliniczne prowadzone na świecie potwierdzają skuteczność metody, otwierając nowe perspektywy dla jej zastosowania w terapii konwencjonalnej.
The stand for research on Boron Neutron Capture Therapy (BNCT) at the MARIA Reactor at the National Centre for Nuclear Research is being created. The therapy consists of irradiation of the tumour with a neutron beam with specific parameters after prior administration of the boron compound to the patient, which accumulates mainly in cancer cells as a result of specific mechanisms. As a result of 10B(n,α)7Li reaction, ionising particles are emitted and destroy only those cells, in which boron is accumulated. Clinical trials conducted in the world show relatively high efficiency of BNCT, opening new perspectives for its use in conventional therapy.
Źródło:
Inżynier i Fizyk Medyczny; 2019, 8, 4; 289-295
2300-1410
Pojawia się w:
Inżynier i Fizyk Medyczny
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
A study about the measurement method of the homogeneity of radioactivity along an iridium-192 wire used in brachytherapy
Autorzy:
Costa, O. L.
Calvo, W. A. P.
Zeituni, C. A.
Rostelato, M. E. C. M.
Moura, J. A.
Feher, A.
Souza, C. D.
Somessari, S. L.
Powiązania:
https://bibliotekanauki.pl/articles/148238.pdf
Data publikacji:
2014
Wydawca:
Instytut Chemii i Techniki Jądrowej
Tematy:
iridium-192
iridium wire
low dose rate brachytherapy
quality control
cancer treatment
radioactive sources production
Opis:
The Nuclear and Energy Research Institute has produced, since 1998, iridium-192 wires used in low dose rate brachytherapy. In the paper the authors studied the influence of wire profile on the homogeneity distribution of radioactivity of iridium-192 along the wire. The authors propose the improvements in the quality control procedure that will provide more accurate measurement data and suggest changes in control devices.
Źródło:
Nukleonika; 2014, 59, 1; 37-39
0029-5922
1508-5791
Pojawia się w:
Nukleonika
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Akcelerator Intraline-IOERT do radioterapii śródoperacyjnej
The IOERT IntraLine Accelerator for Intraoperative Radiotherapy
Autorzy:
Pracz, J.
Syntfeld-Każuch, A.
Powiązania:
https://bibliotekanauki.pl/articles/214331.pdf
Data publikacji:
2017
Wydawca:
Instytut Chemii i Techniki Jądrowej
Tematy:
akcelerator elektronów
śródoperacyjna terapia wiązką elektronów
leczenie nowotworów
electron accelerator
Intraoperative Electron Radiation Therapy
cancer treatment
Opis:
Artykuł przedstawia opracowany w Narodowym Centrum Badań Jądrowych we współpracy z Wielkopolskim Centrum Onkologii mobilny akcelerator IntraLine-IOERT, który jest przeznaczony do napromieniania podczas wykonywanych w salach operacyjnych zabiegów chirurgicznych. Akcelerator generuje terapeutyczną wiązkę elektronów o energii od 4 do 12 MeV, którą można wykonywać napromienianie pól o średnicy od 3 do 10 cm poprzez zastosowanie odpowiednich aplikatorów. Konstrukcja akceleratora zapewnia pełną mobilność całego akceleratora, a w szczególności jego głowicy, co pozwala na wyprowadzenie wiązki elektronów pod różnymi kątami zależnie od położenia komórek nowotworowych w ciele pacjenta.
In the article the mobile electron accelerator IntraLine-IOERT developed by National Centre of Nuclear Research in cooperation with The Greater Poland Cancer Centre is presented. The unit is designed for use during surgical procedures in an operating room (Intraoperative Electron Radiation Therapy). The device generates therapeutic electron beam with the energy from 4 MeV to 12 MeV and it allows to irradiate fields of the diameter from 3 to 10 cm using a suitable applicator. IntraLine-IOERT accelerator is a fully mobile device; especially its mobile head allows for easy application of the electron beam under different angels as required by the tumor location in a patient’s body.
Źródło:
Postępy Techniki Jądrowej; 2017, 3; 21-28
0551-6846
Pojawia się w:
Postępy Techniki Jądrowej
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Sposoby zapobiegania niepłodności u chorych leczonych z powodu nowotworów
Preservation of fertility in oncologic patients
Autorzy:
Markowska, Anna
Pawałowska, Monika
Powiązania:
https://bibliotekanauki.pl/articles/1030835.pdf
Data publikacji:
2010
Wydawca:
Medical Communications
Tematy:
cancer treatment
fertility after oncologic treatment
fertility enhancement
fertility preservation
infertility
leczenie onkologiczne
niepłodność
płodność po leczeniu przeciwnowotworowym
techniki wspomaganego rozrodu
zachowanie płodności
Opis:
Significant progress in oncology over the past years resulted in a noticeable improvement of mean survival rates of patients treated for malignant tumors. Particularly rewarding is the treatment of tumors in the pediatric and juvenile age group. A sizeable proportion of patients subjected to oncologic treatment, i.e. chemotherapy, radiotherapy and surgery, experience a limited procreative potential as a sequel of administered therapy. Among chemotherapeutics, some of the most toxic compounds are alkylating agents, e.g. cyclophosphamide, chlorambucil, melphalan and procarbazine. Severity of negative effects of cytostatics on the patients’ fertility depends largely on administered dose and patient’s age at the time of treatment. In the case of radiotherapy, severity of limitation of procreative potential correlates with total absorbed dose of radiation, irradiated body area and, as in the case of chemotherapy, on the patient’s age. Induced iatrogenic infertility is a tremendous problem for survivors, adversely affecting their quality of life. Apart of inherited genetic syndromes, no evidence is available suggesting that oncologic treatment instituted in the past in the parents might increase the risk of cancer or congenital malformations in their offspring. Thanks to the development of novel procreation-enhancing techniques, several options are currently available enabling preservation of procreative potential of oncologic patients. Prior to institution of antitumor therapy, persons who wish to preserve fertility should be offered cryopreservation of embryos, oocytes, sperm or of a sample of gonadal tissue, transposition of ovaries or hormonal suppression of oogenesis and spermatogenesis. Implementation of these techniques should provide young people with a chance to raise their own children.
Dzięki znacznemu postępowi w dziedzinie onkologii w ciągu kilku lat istotnie wzrósł średni czas przeżycia pacjentów leczonych z powodu nowotworów złośliwych, a szczególnie duże powodzenie odnotowuje się w leczeniu nowotworów wieku dziecięcego i młodzieńczego. Niemała liczba młodych osób przechodzących w przeszłości leczenie onkologiczne, w postaci chemioterapii, radioterapii, leczenia chirurgicznego, ma ograniczone możliwości prokreacyjne ze względu na zastosowaną terapię. Wśród chemioterapeutyków do najbardziej toksycznych substancji należą związki alkilujące, tj. cyklofosfamid, chlorambucyl, melfalan i prokarbazyna, przy czym stopień negatywnego oddziaływania cytostatyków na płodność pacjentów zależy w dużej mierze od zastosowanej dawki leku oraz wieku chorego. W przypadku radioterapii ograniczenie zdolności prokreacyjnych związane jest z całkowitą pochłoniętą dawką promieniowania, z polem napromieniania oraz, podobnie jak w przypadku chemioterapii, z wiekiem pacjenta. Wyindukowana jatrogennie bezpłodność stanowi olbrzymi problem dla ozdrowieńców, znacząco obniża ich jakość życia. Poza dziedzicznymi zespołami genetycznymi nie ma dowodów na to, że zastosowana w przeszłości u rodziców terapia przeciwnowotworowa zwiększa ryzyko raka albo wad wrodzonych u potomstwa. Dzięki rozwojowi technik wspomaganego rozrodu istnieje obecnie wiele metod pozwalających zachować zdolności rozrodcze u pacjentów onkologicznych. Przed rozpoczęciem terapii przeciwnowotworowej u osób pragnących zachować płodność należy zaproponować zamrożenie zarodków, oocytów, nasienia, fragmentu tkanki gonadalnej, transpozycję jajników lub hormonalną supresję oogenezy i spermatogenezy. Stosując ww. techniki, daje się tym młodym ludziom szansę na uzyskanie własnego potomstwa.
Źródło:
Current Gynecologic Oncology; 2010, 8, 4; 273-284
2451-0750
Pojawia się w:
Current Gynecologic Oncology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Assessment Of the surgical treatment results IN patients with colorectal cancer IN A district hospital versus treatment results IN A highly specialized center
Autorzy:
Ciesielski, Przemysław
Berut, Maciej
Górnicki, Krzysztof
Skoczylas, Jacek
Gorajska, Maja
Żuk, Marcin
Rutkowski, Andrzej
Dłubek, Justyna
Powiązania:
https://bibliotekanauki.pl/articles/1393874.pdf
Data publikacji:
2016
Wydawca:
Index Copernicus International
Tematy:
colorectal cancer
the results of treatment of colon cancer
Opis:
In Poland there there are about 15‑16 thousand cases of colon cancer per year. The health care system allows the treatment of patients with colorectal cancer in highly specialized hospitals, oncology centers and district hospitals. The results of treatment within different reference level differ. The aim of the study was to evaluate the results of surgical treatment of patients with colorectal cancer at a district hospitals compared with the results of highly specialized center. Material and methods. A retrospective study. The material consisted of 171 consecutively operated patients diagnosed with colorectal cancer treated in the Department of Surgery, District Hospital in Wołomin. The control group consisted of 200 patients treated surgically at the Department of General and Colorectal Surgery, University Hospital in Łódź. In both centers, the patients were operated on by surgeons with experience in operations on the large bowel. The demographic data, information on the type of indication (elective vs emergent), and the severity of the disease by AJCC / TNM scale were collected. In the district hospital there were patients with more advanced disease (p <0.001), older (p = 0.0001), and often operated under emergent indication (p = 0.0001). The telephone survey collected data on survival or the date of death of the patient and set the percentage of five-year survival. Results. The proportion of five-year survival in the study group and control group was respectively 46% and 71% (p <0.0001). The percentage of five-year survival among patients undergoing elective procedure in both centers were respectively for Wołomin and Łódź 58% and 73% (p = 0.008). The proportion of 5-year survival among “younger” patients (<70) was respectively in Wołomin and Łódź 64% and 81% (p = 0.004) for “older” patients with (> 70) 50% and 60% (p = 0.6747) Conclusions. Overall results of surgical treatment of patients with colorectal cancer in the district hospital are inferior to treatment results in a highly specialized center. The population treated in the district hospital is statistically significantly different in comparison to patients treated in highly specialized center. The following differences were captured: severity of the disease, age and type of indication (elective vs emergent). The diffrences has an influence on the outcomes. The five years survival for patients > 70 years undergoing elective procedure is not statistically different between the district hospital and highly specialized center.
Źródło:
Polish Journal of Surgery; 2016, 88, 4; 188-195
0032-373X
2299-2847
Pojawia się w:
Polish Journal of Surgery
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Wyniki leczenia operacyjnego raka nerki w I Klinice Urologii Uniwersytetu Medycznego w Łodzi w latach 2004–2010
Results of surgical treatment of kidney cancer in the Department of Urology, Medical University of Lodz in 2004–2010
Autorzy:
Kierstan, Andrzej
Jabłonowski, Zbigniew
Sosnowski, Marek
Powiązania:
https://bibliotekanauki.pl/articles/1032607.pdf
Data publikacji:
2016
Wydawca:
Łódzkie Towarzystwo Naukowe
Tematy:
rak nerki
leczenie operacyjne
kidney cancer
surgical treatment of kidney cancer
Opis:
Introduction. Aim of the study: The only effective treatment method for all forms of the kidney cancer is surgery with possible subsequent institution of neoadjuvant treatment. The standard management involves nephrectomy with or without lymphadenectomy and adrenalectomy. In patients with kidney tumors up to 4 cm in diameter, surgical procedures saving the renal parenchyma (Nephron-Sparing Surgery – NSS) are currently performed. The objective was the retrospective analysis of the treatment results obtained in renal cancer patients who had undergone surgical procedures. The results of the treatment following nephrectomy performed from transperitoneal and retroperitoneal approach were compared with those obtained after NSS type procedures. Material and methods: The study was carried out in 238 patients: 107 women and 131 men with kidney cancer, operated on in the years 2004 – 2010. In 15 patients distant metastases were found. The nephrectomy was performed in 69 patients from transperitoneal access and in 105 patients from retroperitoneal access with NSS procedures in 55 patients. The transperitoneal approach was used in patients with large tumors ranging > 6 cm size. Other patients were operated on with lumbar access, also those with tumors < 4 cm, since that approach was used for NSS procedures. The intraoperative and postoperative period, the duration of the surgery, complications, hospitalization time, analgesic treatment and overall survival were evaluated. Results: The operated patients were hospitalized for 11 days on the average, and the mean time of the surgical procedure was ca. 168 minutes. Intraoperative blood loss during most of the performed procedures was without clinical significance but the largest blood loss during the operation was reported in the patients with kidney tumors > 10 cm during transperitoneal access surgery. The blood loss was compensated in 33 cases by the administration of RBC preparations in 21.74% of the patients after transperitoneal access surgeries and 10.65% of those after lumbar access. Retroperitoneal access was associated with the use of larger quantities of analgesic medications in the postoperative period. Histopathological investigations resulted with clear cell carcinoma in 85% of the patients, in other 15% of the cases, most commonly diagnosed with chromophobe and papillary carcinomas. The malignancy grade of RCC according to Fuhrman scale; Fuhrman 1 – 7.98%, Fuhrman 2 – 61.38%, Fuhrman 3 – 9.66%, Fuhrman 4 – 5.88%. Fuhrman grades 3 and 4 were, however, more common in the patients with the big tumors undergoing transperitoneal access. The local advancement of the removed kidney tumors according to TNM classification: stage pT1 in 156 patients, stage pT2 in 52 and pT3 in 1 patient. The distribution of diagnoses and staging was similar for both surgical approaches. The results of kidney cancer treatment were reflected by the assessment of 5–year survival of the patients. Such analysis was possible only in the subgroup of 115 patients who had undergone the surgery in the years 2004 – 2007. The obtained data indicated the overall 5–year survival rate amounting to 58.3% of the reviewed subgroup, whereas 48 patients, i.e. 41.7% died. The causes of death were not possible to know. It is noteworthy that the group of deaths included all the patients operated on at the metastatic stage of the disease. Conclusions: In large renal tumors > 6 cm size, transperitoneal access nephrectomy was preferred. In the remaining patients lumbar access procedures were performed, including kidney-sparing surgery. Fuhrman grade 3 and 4 clear cell tumors are predominant in the patients operated on with transperitoneal access. The number of intra- and postoperative complications is similar in both groups. The use of transperitoneal access is associated with an increase in the amount of analgesics administered in the postoperative course, longer duration of the surgical procedure and longer hospitalization time. The overall 5–year survival rate for the group of 115 patients operated on in the years 2004–2007 was 58.3%.
Źródło:
Folia Medica Lodziensia; 2016, 43, 1; 53-68
0071-6731
Pojawia się w:
Folia Medica Lodziensia
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The role of new biomarkers for the diagnosis and treatment of colon cancer
Autorzy:
Czarnecka-Czapczyńska, Magdalena
Bartusik-Aebisher, Dorota
Krupka-Olek, Magdalena
Aebisher, David
Cieślar, Grzegorz
Latos, Wojciech
Kawczyk-Krupka, Aleksandra
Powiązania:
https://bibliotekanauki.pl/articles/2040510.pdf
Data publikacji:
2021-12-30
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
colon cancer
diagnosis
treatment
Opis:
Introduction. Colorectal cancer may be benign or malignant. According to the World Health Organization and CDC, it is the second most common cancer worldwide, after lung cancer. The mortality of colorectal cancer has been dropping for more than 20 years due to the improvements in screening techniques and treatments. Aim. The aim of this article is to discuss the role of new biomarkers for the diagnosis and treatment of colon cancer. Material and methods. This article is a review done in regards to discuss the role of new biomarkers for the diagnosis and treatment of colon cancer. Analysis of the literature. A review is discussed the role of new biomarkers for the diagnosis and treatment of colon cancer using current literature. Conclusion. The screening tests based on diagnostic new biomarkers may cause faster detection of cancer and risk factors, and provide prognostic information in order to adjust individual therapy.
Źródło:
European Journal of Clinical and Experimental Medicine; 2021, 4; 326-329
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Time to treatment of prostate cancer patients
Autorzy:
Rucińska, Monika
Osowiecka, Karolina
Gałka, Szymon
Środa, Radosław
Wojciechowski, Piotr
Sugajska, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1035802.pdf
Data publikacji:
2018
Wydawca:
Medical Education
Tematy:
prostate cancer
waiting for treatment
Opis:
Prostate cancer is one of the most common cancers in men. The incidence of prostate cancer increases systematically. The correlation between waiting time for oncological treatment and survival prognosis in prostate cancer is not clearly determined. The aim of the study was to estimate the waiting time from suspicion until prostate cancer diagnosis and treatment in Warmia and Mazury Voivodeship. Ninety-six consecutive prostate cancer patients treated with radical radiotherapy between November 2016 and June 2017 in the Department of Radiation Oncology of the Hospital of the Ministry of Internal Affairs with Warmia and Mazury Oncology Center in Olsztyn were included in the analysis. A questionnaire prepared especially for this study, and individual interviews with patients were used in the study. The obtained data was supplemented with medical records and hospital databases. In the case of twenty-nine men, the PSA concentration was measured due to urinary disorders, and the median time from symptoms until the first PSA test in that group was 168 days. The median time from PSA concentration > 4 ng/ml to biopsy of prostate cancer and start of treatment for all patients was 62 and 156 days, respectively. Hormone therapy was administered the quickest. A positive correlation was observed between the waiting time from histopathological confirmation of prostate cancer until treatment, and the distance from one’s place of residence to the oncological center (p < 0.05).
Źródło:
OncoReview; 2018, 8, 3; 86-93
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Risk analysis for the surgical treatment of colorectal cancer in elderly patients undergoing scheduled and urgent interventions
Autorzy:
Pelzer, Oskar
Kielan, Wojciech
Powiązania:
https://bibliotekanauki.pl/articles/1395714.pdf
Data publikacji:
2014-02-01
Wydawca:
Index Copernicus International
Tematy:
colorectal cancer
elderly
surgical treatment
Opis:
Due to recorded growth both in living standards and latest researches in medicine, proportion of people in old age has significantly improved all over the world. Although old age people are several percent of the entire society, number of surgeries within the group does not exceed 40%. Also risk of malignant neoplasms among old age people, significantly grows. Malignant neoplasm of colon appears to be most visible problem in group of people in age over 75 years old. The aim of the study was a retrospective analysis of results in treatment of the sick over 75 years old, suffering from Malignant neoplasm of colon. Therapy was performed in the I Unit of General Surgery and Surgical Oncology in Provinical Hospital in Jelenia Góra. Material and methods. Subject to analysis were 63 patients that went under operations in years from 2006 to 2010 due to the colorectal cancer, who have been divided now into two groups. First group included 49 patients treated as per schedule, and the second stood for 14, who required urgent treatment. Reference group has involved 20 younger patients, treated in urgent and scheduled courses, due to the colon cancer. There are no contradictions to emergencies and scheduled surgeries for patients in advanced years, suffering from colon cancer. Complications after colon cancer emergencies are far more frequent than in case of scheduled surgeries. Death rates among patients over 75 years old are far more frequent after emergencies than after scheduled surgeries. Concomitant diseases occur the same frequent during emergenices as during scheduled operations. During emergencies, it was left side of the colon that occured to be infected with cancer more frequent. Conclusions. There is no significant diversity in hospitalization time frames after emergencies and scheduled surgeries. Dangerous surgical complications within group of older patients, those after emergencies and scheduled surgeries too, are far more frequent in comparison to the reference group.
Źródło:
Polish Journal of Surgery; 2014, 86, 2; 61-67
0032-373X
2299-2847
Pojawia się w:
Polish Journal of Surgery
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Współczesne możliwości oszczędzenia zdolności do rozrodu u kobiet leczonych z powodu nowotworów narządu rodnego
Modern therapeutic modalities enabling preservation of procreative potential in women treated for genital malignancies
Autorzy:
Panek, Grzegorz
Sobiczewski, Piotr
Derlatka, Paweł
Gmyrek, Jarosław
Ziółkowska-Seta, Izabela
Powiązania:
https://bibliotekanauki.pl/articles/908262.pdf
Data publikacji:
2006
Wydawca:
Medical Communications
Tematy:
endometrial cancer
ovarian cancer
preservation of fertility
sparing treatment
uterine cervix cancer
Opis:
Recent decade saw a significant progress in the diagnosis of prognostically important features of neoplasm, in particular those influencing critically the choice of techniques and protocols of oncological treatment. Principles of therapeutic approach to patients with genital malignancies, which were valid in the past, most often neither took into consideration the age of patients, nor was the issue of preservation of procreative functions considered as clinically important. In recent years, the situation in this area underwent a dramatic change. In patients of procreative age, the measure of therapeutic success is not as much standard parameters, e.g. long-term survival rate or recurrence risk, but rather overall quality of life and in particular preservation of ability to procreate. At present, in most locations of early-stage female genital malignancy, there is a possibility to spare procreative function. Based on reports in recent publications, we undertook a review of current views on management of malignancies of uterine cervix, uterine mucosa and ovary enabling preservation of procreative potential of women involved.
Ostatnie dziesięciolecie to czas, w którym dokonał się znaczący postęp w rozpoznawaniu istotnych prognostycznie czynników charakteryzujących nowotwór, zwłaszcza tych, które w sposób znaczący wpływają na wybór metody leczenia onkologicznego. Obowiązujące w przeszłości zasady postępowania terapeutycznego stosowane w leczeniu nowotworów złośliwych narządu rodnego najczęściej nie uwzględniały wieku pacjentek i możliwości oszczędzenia funkcji rozrodczych jako istotnego klinicznie elementu. Sytuacja w tym zakresie uległa w ostatnich latach zasadniczej zmianie. U chorych w wieku rozrodczym miarą sukcesu terapeutycznego są obecnie nie tylko typowe parametry, jak odsetek wieloletnich przeżyć czy też ryzyko nawrotu, ale również jakość życia – w tym szczególnie zachowanie zdolności do rozrodu. Obecnie w większości lokalizacji wczesnych postaci nowotworów narządów płciowych kobiecych istnieje możliwość oszczędzenia zdolności do prokreacji. Bazując na doniesieniach współczesnego piśmiennictwa, dokonano przeglądu aktualnych stanowisk i opinii na leczenie nowotworów szyjki macicy, błony śluzowej macicy oraz jajnika z oszczędzeniem zdolność do rozrodu.
Źródło:
Ginekologia Onkologiczna; 2006, 4, 4; 230-240
1731-5379
Pojawia się w:
Ginekologia Onkologiczna
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 99

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies